Zymeworks Inc. is a global biotechnology company building a diversified portfolio of healthcare assets. The Company's asset and royalty aggregation strategy combines a portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. The Company's portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by it and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using the Company's proprietary antibody engineering technologies. The Company is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its product candidates include ZW191, ZW251, ZW220, ZW209 and ZW1528.
Back to dashboard
Company Information
About this company
Key people
Kenneth H. Galbraith
Chairman of the Board, President, Chief Executive Officer
Susan M. Mahony
Lead Independent Director
Brian N. Cherry
Director
Carlos E. Campoy
Independent Director
Alessandra Cesano
Independent Director
Gregory A. Ciongoli
Independent Director
Kristin Stafford
Chief Financial Officer, Executive Vice President
Mark Hollywood
Chief Operating Officer, Executive Vice President
Laura O'Connor
Senior Vice President, Chief Human Resources Officer
Scott Platshon
Executive Vice President, Chief Business Officer
Bijal Desai
Senior Vice President - Finance
Lindsey Foulkes
Senior Vice President - Corporate Development and Strategy
Sabeen Mekan
Senior Vice President, Chief Medical Officer
Paul A. Moore
Chief Scientific Officer
Click to see more
Key facts
- Shares in issue70.96m
- EPICZYME
- ISINUS98985Y1082
- LocationCanada
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.88bn
- Employees231
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.